Monopar presents ALXN1840 late-breaker data at EASL showing sustained efficacy and safety over 2.6 years

Monopar Therapeutics

Pooled analysis from three trials (n=255) shows sustained improvements in UWDRS Part II/III and copper mobilization.
Fewer than 5% of patients had a drug-related serious adverse event; no renal/urinary SAEs reported.
ALXN1840 improved CGI-I and New Wilson Index vs. standard of care; patients reported higher convenience.
Median treatment duration 961 days (efficacy) and 943.5 days (safety) across four trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.